Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pollinex Quattro Birch for birch pollen allergic rhinoconjunctivitis
2016-002781-31Phase 3Completed
- Sponsor
- Allergy Therapeutics PLC
- Start
- Nov 2016
- Modality
- Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of depigoid birch in allergic rhinoconjunctivitis (ARC) and seasonal allergic rhinitis (SAR) (4 arms), sponsored by Allergy Therapeutics PLC. Primary endpoint: Total combined symptom medication score over peak birch pollen season. Started Nov 2016; status: completed.
02
Drugs
depigoid birch
03
Conditions
allergic rhinoconjunctivitis (ARC)seasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on 2016-002781-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002781-31.